News

Collaboration Between 858 Therapeutics and OpenBench in Drug Discovery

Collaboration Between 858 Therapeutics and OpenBench in Drug Discovery

Collaboration in Small Molecule Drug Discovery

858 Therapeutics and OpenBench have joined forces to undertake a significant collaboration focused on the discovery of small molecule inhibitors. This partnership aims to harness OpenBench’s advanced structure-based machine learning platform, enhancing the drug discovery process. The initial phase of this collaboration will concentrate on a target that remains undisclosed but is nominated by 858 Therapeutics.

Terms of the Agreement

According to the agreement, both companies will work together to navigate through the drug discovery landscape, particularly up to hit validation. OpenBench is tasked with the identification of new and potentially developable chemical series. Once these series are discovered, 858 Therapeutics will conduct characterization and validation through their proprietary biochemical, biophysical, and cellular assays. Notably, OpenBench has the opportunity to earn milestone payments based on the success of novel chemotypes that align with specific molecular properties outlined by 858 Therapeutics. As part of the collaboration, 858 will gain complete and exclusive rights to any acquired chemotypes and be solely accountable for their future research and development. While comprehensive financial details of this agreement remain undisclosed, it signifies a substantial commitment from both parties.

Leadership Insight

Expressing enthusiasm for the new venture, Jeffrey Stafford, Ph.D., the CEO of 858 Therapeutics, emphasized the exciting nature of the collaboration, stating, “We are excited to launch this collaboration with OpenBench. Through its proprietary AI platform, the OpenBench team has built a track record of identifying novel, tractable chemical matter against challenging targets.” His perspective showcases a forward-thinking vision aimed at creating innovative therapies.

OpenBench's Perspective

Lewis Martin, Ph.D., the Chief Scientific Officer of OpenBench, echoed similar sentiments, highlighting the distinctive strengths of 858 Therapeutics. He mentioned, “858 has an innovative pipeline borne of deep biological insight into novel targets. We are thrilled to apply our specialized discovery approach to enrich their vision of bringing new therapies to patients.” This outlook contributes to a robust and synergistic partnership geared towards tackling pressing medical challenges.

About 858 Therapeutics

Located in the vibrant biotech hub, 858 Therapeutics focuses on developing a range of small molecule therapeutics that target novel oncology and immunology aspects. Their primary initiatives revolve around key areas of cancer biology, emphasizing critical nodes such as DNA damage repair, innate immunity, and RNA epigenetics. With a strong pipeline and a commitment to innovation, 858 Therapeutics stands at the forefront of biotechnological advancements.

About OpenBench

OpenBench is transcending traditional drug discovery methodologies by fostering success-driven collaborations. This pioneering model aims to bolster early discovery processes through AI integration, allowing for effective virtual screening, custom synthesis, and experimental validation while ensuring every dollar spent is directed towards identifying potent, developable hits. Their proprietary structure-based machine learning platform has proven successful in locating quality, progressible chemical matters for over 90% of targets addressed thus far, indicating robust efficacy in their approach.

Frequently Asked Questions

What is the focus of the collaboration between 858 Therapeutics and OpenBench?

The collaboration primarily aims to discover small molecule inhibitors using OpenBench's advanced structure-based machine learning platform, focusing on an undisclosed target nominated by 858 Therapeutics.

How will success be measured in this collaboration?

Success will be gauged via hit validation and milestone payments for novel chemotypes that adhere to specific molecular properties laid out by 858 Therapeutics.

What are the key areas of focus for 858 Therapeutics?

858 Therapeutics centers its efforts on small molecule therapeutics targeting notable sectors of oncology and immunology, including DNA damage repair and RNA epigenetics.

What unique methodologies does OpenBench implement in drug discovery?

OpenBench employs a success-driven collaboration model that leverages AI, ensuring costs are effectively used for developing potent, viable hits from the beginning of the partnership.

Is there any financial information available regarding the collaboration?

While detailed financial terms were not disclosed, it is indicated that OpenBench may receive milestone payments based on the success of the chemical series identified.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 85

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 246

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading

Top 5 Most Recently Viewed Articles

RegScale Secures FedRAMP High Authorization: A Game-Changer

Updated Category News Views 263

RegScale Secures FedRAMP High Authorization RegScale, utilizing its innovative Continuous Controls Monitoring platform, has reached the notable milestone of obtaining FedRAMP High Authorization, demonstrating a significant advancement in compliance and risk management within the government sector. This achievement showcases RegScale's commitment to enhancing security...

Continue Reading
SiriusXM Improves Financial Guidance Amid Digital Growth

Updated Category News Views 214

SiriusXM Holdings Inc Experiences Stock Surge SiriusXM Holdings Inc (NASDAQ:SIRI) saw its stock prices climb significantly following the release of its fiscal third-quarter results. Investors responded positively as the company’s future outlook showed promise for expansion. Positive Financial Results The report revealed a subscriber revenue of $1.63 billion for the...

Continue Reading
Explore Top Free AI Image Translators for Your Needs

Updated Category News Views 288

Unlocking the Power of Image Translation Translating text from images is a crucial task in today’s digital world. Whether you need to read signs, understand menus, interpret social media posts, or analyze product reviews, having a reliable image translator can make a significant difference. The right tools not only improve accuracy but also support multiple languages,...

Continue Reading
Exciting Collaboration Unveiled: REESE'S and OREO Join Forces

Updated Category News Views 240

An Exciting New Collaboration The anticipation has been palpable among fans of REESE'S and OREO, and now, the moment has arrived. These iconic brands, celebrated for their unique flavors, are thrilled to present a delectable collaboration that combines their most popular offerings. This partnership responds directly to the enthusiasm and demand expressed by fans....

Continue Reading
Innovative Clinical Research Enhances Care for Cancer Patients

Updated Category News Views 440

Innovative Research at Florida Cancer Specialists Clinical research at Florida Cancer Specialists & Research Institute is making significant strides in expanding treatment options for patients dealing with gastrointestinal and genitourinary cancers. This knowledgeable institute is at the forefront of developing and presenting vital research that contributes to improved...

Continue Reading